Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 70 versus PANTOPAQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 70 versus PANTOPAQUE.
OMNIPAQUE 70 vs PANTOPAQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast by increasing the density of blood vessels and organs.
Pantopaque is an iodinated oil-based contrast agent that attenuates X-rays, allowing visualization of the subarachnoid space during myelography. It acts as a positive contrast medium by increasing the absorption of X-rays in the cerebrospinal fluid.
1.5-2.0 mL/kg IV for contrast enhanced CT, max 150 mL; intra-arterial: 5-40 mL per injection depending on procedure.
Adults: 5-15 mL (6-18 g iophendylate) intrathecally for myelography via lumbar puncture. No repeated dosing.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe dysfunction).
Terminal elimination half-life is approximately 6 hours in patients with normal renal function. In renal impairment, half-life is significantly prolonged (up to 24–48 hours in severe impairment), requiring dose adjustment or avoidance.
Renal: 100% unchanged via glomerular filtration. No biliary or fecal elimination.
Primarily renal (glomerular filtration) with approximately 60-70% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5% of the administered dose; minor metabolism occurs, but the majority is eliminated unchanged via kidneys.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent